Silicon Valley Capital Partners »

Halozyme Therapeutics shares owned by Silicon Valley Capital Partners

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Silicon Valley Capital Partners from 13F filings

Historical chart of Silicon Valley Capital Partners investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Silicon Valley Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Silicon Valley Capital Partners

Quarter filed Position value Share count Share price at filing
2023-12-31 $11k 300 36.96

More positions owned by Silicon Valley Capital Partners

Spdr S&p 500 Etf Trust Etf (SPY)
Invesco S&p 500 Garp Etf Etf (SPGP)
Invesco Qqq Trust Series I Etf (QQQ)
Apple Stock (AAPL)
Vanguard Information Technology Etf Etf (VGT)
Microsoft Corp Stock (MSFT)
Alphabet Inc Cap Stk Cl A Stock (GOOGL)
Nvidia Corporation Stock (NVDA)
Ishares S&p 500 Growth Etf Etf (IVW)
Amazon Stock (AMZN)
Vanguard Growth Etf Etf (VUG)
Vanguard Mega Cap Value Etf Etf (MGV)
Goldman Sachs Activebeta U.s. Large Cap Equity Etf Etf (GSLC)
Berkshire Hathaway Inc Del Cl B Stock (BRK.B)
Starbucks Corp Stock (SBUX)

View all positions for Silicon Valley Capital Partners

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
Artisan Partners Limited Partnership
Alliancebernstein
Jpmorgan Chase & Co
Geode Capital Management
TD Asset Management
Jennifer Ranahan
Dimensional Fund Advisors
Charles Schwab Investment Management
Nuveen Asset Management
Arrowpoint Asset Management
Goldman Sachs Group
T. Rowe Price Associates
Norges Bank Investment Management

View all funds holding Halozyme Therapeutics